November 10, 2014 News by Patricia Silva, PhD MS Patients Being Evaluated as Fit to Work, Receiving Lower Benefits, Charities Alert Patients who suffer from progressive conditions, such as multiple sclerosis (MS), are submitted to unnecessary evaluations for disability benefits and often denied the full payment of their out-of-work benefits or deemed as fit to work when they are in fact not able. This new perspective was highlighted by a…
November 7, 2014 News by Patricia Silva, PhD Biogen Idec Gives $1.4M to New MS Research Program in Alberta Photo From University of Alberta The company behind FDA-approved multiple sclerosis drug AVONEXĀ® (Interferon beta-1a), Biogen Idec, together with the government of the province of Alberta, has…
November 5, 2014 News by Patricia Silva, PhD Teva and Active Biotech Expand Investigational MS Treatment Program Drug manufacturersĀ Teva Pharmaceutical Industries Ltd.Ā and Active Biotech announced that they expanding the ongoing clinical research program for the study ofĀ laquinimod, a potential treatment for primary progressive multiple sclerosis (PPMS), as the companies are now initiating theĀ ARPEGGIO trial. In addition, Teva has also announced…
November 5, 2014 News by Patricia Silva, PhD Genzyme Clinical Trial for Relapsing-Remitting MS Enrolls 1st Patient Sanofi subsidiary and rare disease treatment specialistĀ GenzymeĀ has just announced the successful enrollment of the first participant in their multicenter Phase II clinical trial for the company’s pipeline intravenous drug forĀ relapsing-remitting multiple sclerosis (RRMS), vatelizumab. This novel drug is composed of humanized monoclonal antibodies that specifically target…
November 4, 2014 News by Patricia Silva, PhD National MS Society Grants $457,921 to Kessler Foundation Researcher The National Multiple Sclerosis SocietyĀ recently awarded MS researcher Lauren Strober, PhD from the Kessler Foundation, a three-year grant for her investigational research, totaling $457,921. The funding is part of a multi-site study that will be conducted by the investigator to understand the influence that having…
October 29, 2014 News by Patricia Silva, PhD Sydney Bikers Join Efforts to Fundraising on MS Gong Ride Sunday Next Sunday, November 2nd,Ā Sydney, Australia will hold one of the country’s largest fundraising events to support multiple sclerosis research and advocacy, theĀ MS Gong Ride, aĀ one day community bike ride designed to collect $3.8 million. Each biker is asked to help raise $250 for the historic ride that celebrates its…
October 28, 2014 News by Patricia Silva, PhD Philip De Jager Awarded 2014 Barancik Prize for Innovation in MS Research The National Multiple Sclerosis Society granted the 2014Ā Barancik Prize for Innovation in MS Research to Philip Laurence De Jager, MD, PhD, who is a neurologist atĀ Brigham and Women’s Hospital, as well as an associate professor of neurology at the Harvard Medical School. The award, meant to…
October 27, 2014 News by Patricia Silva, PhD Positive Data from Two Key MS Trials Added To Aubagio’s U.S. Label The Food and Drug Administration (FDA) recently accepted the results from Genzyme’s TOWER and TOPIC Ā clinical trials,Ā which assessed the safety and efficacy of oral, once-daily AubagioĀ® (teriflunomide) for Multiple Sclerosis, and will add the positive data to the productās U.S. label. Genzyme is a leader in the development…
October 24, 2014 News by Patricia Silva, PhD MS Society Canada Urges Parliamentarians to Improve MS Clinics While Canada is home to one of the world’s most comprehensive social healthcare systems, it is unfortunately home to one of the largestĀ multiple sclerosisĀ patient populations as well. According to the Multiple Sclerosis Society of Canada, at least 100,000 Canadians have the disease, and at least 20,000 of them live…
October 24, 2014 News by Patricia Silva, PhD Opexa Joins National Multiple Sclerosis Society to Sponsor Walk MS The National Multiple Sclerosis Society‘sĀ Lone Star Chapter, which is sponsoring theĀ nonprofit organizationās annualĀ Houston-area Walk MSĀ fundraisers, has announced that Woodlands-based biopharmaceutical companyĀ Opexa Therapeutics, a company currently developing personalized immunotherapies for multiple sclerosis (MS), will also support the fundraising effort. This is the fourth consecutive…
October 23, 2014 News by Patricia Silva, PhD Consortium of MS Centers Hosts Annual Meeting Next May in Indiana The Consortium of Multiple Sclerosis Centers (CMSC) has announced that its next annual meeting will be held in 2015 between May 27 th and 30th at the JW Marriott Hotel in Indianapolis, Indiana. TheĀ 2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers aims to gather healthcare professionals as…
October 22, 2014 News by Patricia Silva, PhD Dimension Data Helps Raise $130K for National MS Society One of the most effective and engaging fundraising strategies the National Multiple Sclerosis Society organizes annually is the Bike MS series. Several times a year, in different locations throughout the country, thousands of MS patients from all over the world, as well as friends, family, and advocacy…
October 21, 2014 News by Patricia Silva, PhD David Osmond Sings for Novartis MS Awareness Campaign A member of the musical Osmond family, David Osmond, recently released a music video for his inspirational song “I Can Do This.” He has dedicated it to men and women all over the world who are faced with challenges that make them doubt their abilities and self-worth, but the real…
October 20, 2014 News by Patricia Silva, PhD MS Blueprint Online Program by Biogen Helps Patients Live Happier Cambridge, Massachusetts-basedĀ Biogen IdecĀ has just announced a new support program for people living with multiple sclerosis (MS) that encourages patients to turn their attention to daily activities that enhance their emotional and mental state. The newly launched MS Blueprint program assists patients and caregivers in setting positive and realistic goals,…
October 20, 2014 News by Patricia Silva, PhD 5-Course Dinner Raises $445K for Multiple Sclerosis Society of Canada Heartwarming support for multiple sclerosis campaigns and charity events poured in at last week’s exclusive gastronomic fundraising event, theĀ ToquĆ©! for MSĀ benefit, made possible by the tireless, collaborative efforts of Louis Vachon, the event’s Honorary Chair and President and CEO of the National Bank, andĀ ToquĆ©! Restaurant’s Grand Chef Relais & ChĆ¢teaux,…
October 17, 2014 News by Patricia Silva, PhD Free Continuing Education for MS Care Providers Starts in November Several national health organizations have come together to design a series of continuing education opportunities focused on better managing multiple sclerosis entitled,Ā Optimizing Multiple Sclerosis Management.Ā Thanks to the collaborative efforts of leading MS organization for professionals, the Consortium of Multiple Sclerosis Centers (CMSC); Nurse Practitioner Alternatives (NPA), and Spire Learning, allied…
October 16, 2014 News by Patricia Silva, PhD U.S. Supreme Court Gives Teva Mixed Reception on Copaxone Patent Case The U.S. Supreme Court deliberated on a request from Teva Pharmaceutical Industries Ltd. to preserve the patent of its multiple sclerosis drug Copaxone from generic competitors until September 2015. Recent reports indicate that the court gave the company a mixed opinion. The hearing occurred this…
October 16, 2014 News by Patricia Silva, PhD Revenge Star Madeleine Stowe is the New Face of Multiple Sclerosis Featureflash / Shutterstock.com Television’s “Queen of Mean,” Revenge‘s Madeleine Stowe,Ā recently opened up about her early memories of her father living with multiple sclerosis (MS), a progressive neurodegenerative disease that, until today, does not have a known cure. However, thanks to the efforts of countless researchers and MS…
October 15, 2014 News by Patricia Silva, PhD Urinary Prosthesis Better than Catheterization for Female MS Patients One of the concerns patients with neurologic diseases such as multiple sclerosisĀ face is decline or loss of bladder control. It can be an embarrassing and frustrating problem, which is estimated to occur in about 80% of MS patients, as the disease causes a slowing down or interruption in signal transmission…
October 14, 2014 News by Patricia Silva, PhD New Multiple Sclerosis Research Will Focus On Cytokine Regulation, Neuroprotection, Tolerance Induction Evotec AG,Ā a German company specializing in the provision of drug discovery resources to biotech companies and learning institutions, announced that is going to begin three new research projects for the treatment of multiple sclerosis (MS), which will be supported by funds from theĀ German Federal Ministry of Education…
October 14, 2014 News by Patricia Silva, PhD Ankar Pharma Opens Crowdfunding for Promising MS Drug Spanish-Filipino biopharmaceutical startupĀ Ankar PharmaĀ is working on a promising treatment for multiple sclerosis (MS). Dr. Ana Martinez, a professor and researcher at theĀ Biological Research Center (CIB) of the Spanish National Council for Research (CSIC), explains that while there are several palliative treatments available on the market…
October 13, 2014 News by Patricia Silva, PhD PHARMAC Approves Funding New RRMS Treatments in New Zealand New Zealand-basedĀ Pharmaceutical Management Agency (PHARMAC) has approved the funding of new treatments for multiple sclerosis (MS), which are expected not only to reach more patients, but also be more effective in curtailing the disease’s progressive symptoms. The therapies currently funded are meant for the treatment ofĀ …
October 13, 2014 News by Patricia Silva, PhD Alabama Representative Honored at National MS Society Ball The National Multiple Sclerosis SocietyĀ recently honored several admirable MS advocates and leaders during the annual NMSS Ambassadors Ball, held in Washington, D.C., to benefit local MS patients and research initiatives. The upscale black-tie evening brought together some of the most accomplished industry leaders and celebrities at the Georgetown Ritz…
October 10, 2014 News by Patricia Silva, PhD MS Association in Germany Invites Thomas Erning to Present Novel Germany’s Multiple Sclerosis Association is hosting an event dedicated to recognizing those who have devoted much of their time and effort to supporting and empowering MS patients in spite of their debilitating condition. The Chairman, former president Christian Wulff, will be present on Thursday, October 16, in Berlin to…
October 9, 2014 News by Patricia Silva, PhD New Long-lasting Multiple Sclerosis Drug Will Come At a Steep Price Now more than ever, groundbreaking, new therapies for chronic diseases and infections come with high price tags. Earlier in the year, Gilead Sciences’ drugĀ Sovaldi for Hepatitis C, as well as Vertex’s Kalydeco for Cystic Fibrosis, both raised eyebrows over their cost. Now, a new MS therapy is doing the…
October 8, 2014 News by Patricia Silva, PhD NICE Releases New Guidance on Multiple Sclerosis Care The British National Institute for Health and Care Excellence (NICE) updated their guidelines on the provision of health care for multiple sclerosis (MS) patients in the United Kingdom, which number approximately 100,000 people. The institute recommends now that every patient who is suspected to suffer from the…
October 7, 2014 News by Patricia Silva, PhD Oklahoma Medical Research Foundation Receives Multiple Sclerosis Innovation Grant A scientist from the Oklahoma Medical Research Foundation (OMRF) is the recipient of 1 of only 5 Multiple Sclerosis Innovation grants from German biopharmaceutical company EMD Serono. Manu Nair, the foundation’s Vice President of Technology Ventures, said that this funding from a new collaborative relationship is a crucial step towards…
October 3, 2014 News by Patricia Silva, PhD National MS Society Pledges $19 Million Dollars to Fund 54 New Studies 54 new multiple sclerosis (MS)Ā research and development initiatives are set to receive substantial funding in order to accelerate new therapies. The National Multiple Sclerosis Society (NMSS) announced that it has pledged $19 million to fund these new MS studies as part of their mission to better manage…
October 1, 2014 News by Patricia Silva, PhD Glialogix Drug for Progressive MS Funded by National Multiple Sclerosis Society San Francisco Bay Area-based Glialogix, Inc., a biopharmaceutical company that specializes in developing novel treatments for multiple sclerosis (MS), announced yesterday that they have closed aĀ Sponsored Research Agreement with Fast Forward, a non-profit organizationĀ that aims to accelerate MS treatment development.Ā Glialogix will receive funding for one of their…
September 30, 2014 News by Patricia Silva, PhD Multiple Sclerosis Self-Management Scale Enhances Patient Independence Multiple sclerosis (MS) is a chronic, autoimmune neurodegenerative disease that the biomedical research and pharmaceutical industry has yet to find a cure for. It is a progressively debilitating condition that manifests with a number of unpredictable symptoms that can greatly reduce one’s quality of life. In order…